Equities

Arcturus Therapeutics Holdings Inc

ARCT:NMQ

Arcturus Therapeutics Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)16.76
  • Today's Change-0.31 / -1.82%
  • Shares traded355.50k
  • 1 Year change-28.77%
  • Beta2.6207
Data delayed at least 15 minutes, as of Nov 22 2024 20:07 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.

  • Revenue in USD (TTM)160.40m
  • Net income in USD-62.64m
  • Incorporated2019
  • Employees180.00
  • Location
    Arcturus Therapeutics Holdings Inc10628 Science Center Dr Ste 250SAN DIEGO 92121-1132United StatesUSA
  • Phone+1 (858) 900-2660
  • Fax+1 (302) 636-5454
  • Websitehttps://arcturusrx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Allogene Therapeutics Inc43.00k-283.43m442.41m232.00--0.9532--10,288.56-1.53-1.530.00022.210.00007----185.34-43.56-28.46-46.04-30.21-----659,137.20-1,123.44----0.00---39.10--3.86---14.06--
Taysha Gene Therapies Inc9.92m-22.77m446.78m52.00--5.03--45.06-0.0625-0.06250.04210.43330.0527----190,673.10-12.11---27.40-------229.67------0.328--517.55--32.80------
Omeros Corp0.00-185.38m447.93m198.00---------3.14-2.300.00-2.660.00----0.00-45.98-55.51-61.42-70.10-----------6.071.59------3.91---5.56--
Aura Biosciences Inc0.00-83.22m447.94m88.00--2.57-----1.73-1.730.003.510.00----0.00-43.22---46.30--------------0.00-------30.03------
Olema Pharmaceuticals Inc0.00-122.68m450.69m87.00--2.27-----2.19-2.190.003.470.00----0.00-46.92-30.06-51.51-31.40------------0.00------7.76------
Y-mAbs Therapeutics Inc84.55m-23.86m452.37m100.00--4.89--5.35-0.541-0.5411.922.060.6771.134.36845,530.00-19.11-44.23-23.55-50.4588.89---28.22-181.133.54--0.00--29.96--77.58------
Regenxbio Inc84.33m-238.81m454.82m344.00--1.51--5.39-5.03-5.031.766.090.1463--3.27245,136.60-41.43-16.75-51.75-19.0854.3678.27-283.19-72.06----0.00---19.94-16.216.00---5.59--
OmniAB Inc20.41m-63.02m454.93m106.00--1.59--22.29-0.6227-0.62270.20172.430.0564--4.24192,537.70-17.43---18.43-------308.78------0.00---42.17---126.65------
MeiraGTx Holdings PLC13.93m-88.18m456.93m389.00--4.80--32.80-1.30-1.300.21231.230.0492--1.0833,243.44-31.12-26.40-39.74-32.66-7.72---633.05-420.70----0.4324---11.95--35.17--12.37--
Kalvista Pharmaceuticals Inc0.00-141.77m457.69m150.00--2.32-----3.54-3.540.004.010.00----0.00-78.65-40.63-87.52-43.67-------2,972.81----0.00-------36.31---16.34--
Arcturus Therapeutics Holdings Inc160.40m-62.64m462.38m180.00--1.77--2.88-2.33-2.335.959.670.3873--4.69891,105.60-15.13-19.66-18.67-24.90-----39.05-77.55----0.00---19.0360.31-417.95--14.44--
Korro Bio Inc0.00-101.60m470.71m95.00--2.63-----17.04-17.040.0019.280.00----0.00-70.10-31.55-76.20-36.48-------365.87---104.930.00------0.5001--78.21--
Celcuity Inc0.00-93.97m471.39m55.00--3.16-----2.61-2.610.004.030.00----0.00-45.24-37.32-49.93-39.16------------0.393-------57.99---31.12--
Terns Pharmaceuticals Inc0.00-88.07m481.92m66.00--1.33-----1.18-1.180.004.290.00----0.00-27.10-41.34-28.12-45.70-------31,010.30----0.00-------49.49---26.60--
Data as of Nov 22 2024. Currency figures normalised to Arcturus Therapeutics Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

62.02%Per cent of shares held by top holders
HolderShares% Held
Federated Global Investment Management Corp.as of 30 Sep 20244.69m17.36%
Nikko Asset Management Americas, Inc.as of 30 Sep 20242.32m8.56%
BlackRock Fund Advisorsas of 30 Sep 20242.16m7.98%
ARK Investment Management LLCas of 30 Sep 20242.10m7.77%
The Vanguard Group, Inc.as of 30 Sep 20241.52m5.61%
SSgA Funds Management, Inc.as of 30 Sep 20241.47m5.45%
Woodline Partners LPas of 30 Sep 2024779.96k2.88%
Dimensional Fund Advisors LPas of 30 Sep 2024741.36k2.74%
Geode Capital Management LLCas of 30 Sep 2024551.80k2.04%
Fidelity Management & Research Co. LLCas of 30 Sep 2024442.98k1.64%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.